Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18810223 | 0.85 | HRH3 (0.49) | ALDH1A1HRH3SIGMAR1KDM4EUSP2 | |
| SCHEMBL18259694 | 0.81 | LTA4H (0.60) | ALDH1A1HRH3DRD3KDM4E | |
| SCHEMBL4731940 | 0.81 | RAB9A (0.61) | ALDH1A1HRH3DRD3NPC1RAB9A | |
| SCHEMBL20322431 | 0.81 | HRH3 (0.52) | ALDH1A1HRH3DRD3NPC1RAB9A | |
| SCHEMBL1625904 | 0.80 | KDM4E (0.41) | ALDH1A1HRH3KDM4EATM | |
| SCHEMBL3424699 | 0.78 | ALDH1A1 (0.52) | ALDH1A1MEN1RAD52KMT2AHRH3 | |
| SCHEMBL21821894 | 0.78 | HPGD (0.47) | SIGMAR1KDM4EHPGD | |
| SCHEMBL20323753 | 0.78 | HRH3 (0.59) | ALDH1A1HRH3DRD3NPC1RAB9A | |
| SCHEMBL20233909 | 0.78 | HRH3 (0.59) | ALDH1A1HRH3DRD3NPC1RAB9A | |
| SCHEMBL29038419 | 0.77 | FDPS (0.65) | ALDH1A1NPC1RAB9AKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737297-B1 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-19 | — | — | EP | disclosed |
| US-8039498-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-10-18 | — | — | US | disclosed |
| US-8017600-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | disclosed |
| US-8017639-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | disclosed |
| US-7956057-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-07 | — | — | US | disclosed |
| US-7956066-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-07 | — | — | US | disclosed |
| US-7956071-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-07 | — | — | US | disclosed |
| US-7951808-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-7928131-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-20100261899-A1 | IMIDAZOLE COMPOUNDS | BUZARD DANIEL J | 2010-10-14 | — | — | US | disclosed |
| US-7253200-B2 | Using in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-07 | — | — | US | disclosed |
| US-20070173512-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070173509-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070173510-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070173513-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070149541-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-06-28 | — | — | US | disclosed |
| EP-1673348-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-28 | — | — | EP | disclosed |
| US-20050261309-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | US | disclosed |
| WO-2005044807-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
| US-20050070550-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070550-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | ALDH1A1 3379/4885MEN1 4825/4885RAD52 3219/4885 |
| US-20070173512-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | ALDH1A1 3643/4885MEN1 4765/4885RAD52 3954/4885 |
| US-20070173509-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | ALDH1A1 3643/4885MEN1 4765/4885RAD52 3954/4885 |
| US-20070149541-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | ALDH1A1 3643/4885MEN1 4765/4885RAD52 3954/4885 |
| US-20070173510-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | ALDH1A1 3643/4885MEN1 4765/4885RAD52 3954/4885 |
| US-20100261899-A1 | IMIDAZOLE COMPOUNDS | HRH4, HRH3, HRH2 | ALDH1A1 3643/4885MEN1 4765/4885RAD52 3954/4885 |
| US-20070173513-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | ALDH1A1 3643/4885MEN1 4765/4885RAD52 3954/4885 |
| US-20050261309-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | ALDH1A1 3643/4885MEN1 4765/4885RAD52 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.